SPOTLIGHT: S&P likes GTx's Acapodene


Standard & Poor's Equity Research says that GTx is in an enviable position. Late-stage data is due this quarter for Acapodene, an experimental therapy for prostate cancer. "We believe both target markets represent population opportunities of more than 1 million patients." Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.